Stock of the Day - September 29, 2023

Alpha Teknova (TKNO)

$5.42

+$0.10 (+1.9%)

Market Cap: $290.59M

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Today's Trend

Alpha Teknova, Inc. (NASDAQ: TKNO) — The stock is trading higher after the company reported Q4 and full‑year 2025 results, set a multi‑year revenue growth target and announced a recurring commercial investment. Investors appear to be weighing the revenue beat and growth roadmap against conservative FY‑2026 guidance and continued losses.

Company set a long‑term revenue growth target of 20%–25% and will invest roughly $2M per year to build commercial capabilities — signals management is prioritizing scalable growth and go‑to‑market support. Teknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilities
Top‑line momentum: Q4 revenue of ~$10.0M (+8% YoY) and full‑year 2025 revenue of $40.5M (+7% YoY) were in line with guidance — a modest beat vs. near‑term consensus that likely supported the rally. Teknova Reports Fourth Quarter and Full Year 2025 Financial Results
EPS matched analyst consensus at ($0.09) for the quarter; revenue beat but the company remains unprofitable with negative margins and ROE — shows progress on revenue but not yet on profitability. Alpha Teknova Q4 earnings summary
Earnings call transcript and slide deck are available for details on product demand and commercial plans — useful for parsing management’s assumptions behind the growth target and guidance. Alpha Teknova Q4 2025 earnings call transcript
Multiple short‑interest reports in February show anomalous “0 shares / NaN” results — no reliable evidence of a short squeeze or large borrow activity from the provided data. (Data appears to be reporting errors.)
FY‑2026 revenue guidance of $42.0M–$44.0M is slightly below the $44.2M consensus and management did not provide clear EPS guidance — the guidance tempering likely limits upside until execution visibility improves. Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

Bottom line for investors: the market is rewarding top‑line execution and a clearer growth plan, but the stock will likely be sensitive to whether Teknova can convert revenue growth into margin improvement and hit its FY‑2026 targets. Watch upcoming quarterly updates, execution of the $2M commercial spend, and any change to guidance or profitability outlook.

← Previous Stock of the Day Next Stock of the Day →